Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital

Simple item page
dc.article.number1185
dc.catalogadorpva
dc.contributor.authorAcevedo, Francisco
dc.contributor.authorPetric, Militza
dc.contributor.authorWalbaum, Benjamin
dc.contributor.authorRobin, Julieta
dc.contributor.authorLegorburu, Luisa
dc.contributor.authorMurature, Geraldine
dc.contributor.authorGuerra, Constanza
dc.contributor.authorNavarro, Marisel
dc.contributor.authorCanovas, María José
dc.contributor.authorSanchez, Cesar
dc.contributor.authorVargas, Lorena
dc.contributor.authorManzor, Manuel
dc.contributor.authorPeña, José
dc.contributor.authorMuñiz, Sabrina
dc.contributor.authorVeglia, Paulina
dc.contributor.authorCartes, Raúl
dc.contributor.authorMartinez, Raúl
dc.date.accessioned2024-01-19T18:21:49Z
dc.date.available2024-01-19T18:21:49Z
dc.date.issued2021
dc.description.abstractIntroduction: There is extensive evidence associating the response to neoadjuvant chemotherapy (NeoCT) with breast cancer (BC) survival. However, to the author’s knowledge, there is no published data in Chile. The objective of the study is to evaluate whether achieving pathological complete response (pCR) after NeoCT is associated with greater survival and lower risk of recurrence in a Chilean Public Health Service. Methods: Retrospective analysis of a database. Patients with a diagnosis of Stages I–III BC who received NeoCT between 2009 and 2019 were included. Clinical and pathological information were extracted from the clinical records. BC subtypes were defined using hormone receptor (HR) information (HR: oestrogen and/or progesterone) and epidermal growth factor type 2 (HER2), being divided into four groups: HR /HER2−, HR /HER2 , HR−/HER2 , HR-/HER2−. pCR was defined as the absence of invasive cancer in the breast and axilla (ypT0/is N0) after NeoCT. Results: Of 3,092 patients, 17.2% received NeoCT. Of these, 40.2% corresponded to HR /HER2−, 20.9% HR /HER2 , 18.2% HR−/HER2 and 20.7% HR−/HER2−. Overall, 24.8% achieved pCR, being the lowest for HR /HER2− (10.3%) and the highest for HR−/HER2 (53.2%). In the multivariable analysis, family history, HER2 and type of chemotherapy were associated with a greater probability of pCR. With a median follow-up of 40 months, the overall survival and metastasis-free survival (MFS) at 3 years were greater for the group with pCR compared to that which did not achieve it (90.5% versus 76.7%, p = 0.03 and 88.5% versus 71.4%, p = 0.003, respectively). The multivariable analysis confirmed this finding. Brain MFS was similar in both groups. Conclusion: NeoCT is associated with greater pCR in aggressive BC subtypes. In those, achieving pCR was associated with better survival in our study. To the author’s knowledge, this is the first study which evaluates the relation between pCR and BC subtypes in a Chilean public hospital.
dc.fechaingreso.objetodigital2024-06-11
dc.fuente.origenORCID-ene24
dc.identifier.doi10.3332/ecancer.2021.1185
dc.identifier.urihttp://dx.doi.org/10.3332/ecancer.2021.1185
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/80806
dc.identifier.wosidWOS:000618730900001
dc.information.autorucEscuela de Medicina; Acevedo Claros, Francisco Nicolas; 0000-0003-3482-7746; 119540
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final15
dc.pagina.inicio1
dc.revistaecancer
dc.rightsacceso abierto
dc.rights.licenseCC BY 3.0 DEED Attribution 3.0 Unported
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/
dc.subjectBreast cancer
dc.subjectNeoadjuvant therapy
dc.subjectPrognosis
dc.subjectPublic hospital
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleBetter overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital
dc.title.alternativeMejoría en sobrevida global en pacientes que logran respuesta patológica completa luego de quimioterapia neoadyuvante por cancer de mama en un hospital público de Chile
dc.typeartículo
dc.volumen15
sipa.codpersvinculados119540
sipa.trazabilidadORCID;2024-01-08
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Better overall survival in patients who achieve pathological complete response.pdf
Size:
2.01 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas